Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Lauren Bradley

Nurse Practitioner, Primary Care Madera, CA Nurse Practitioner

NPI 1063883551 CMS profile 10558613

9300 Valley Childrens Pl, Madera, CA 93636

Open in the dashboard

General payments

$11,253

357 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Lauren Bradley of Madera, CA is reported in the CMS Open Payments database as having received $11,253 across 357 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Nurse Practitioner, Primary Care profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,755 90
2024 General $1,879 61
2023 General $3,132 74
2022 General $2,190 78
2021 General $1,297 54

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lauren Bradley
  • Nurse Practitioner, Primary Care median
  • Middle half of Nurse Practitioner, Primary Care
  • National median

In program year 2025, general payments to Lauren Bradley were reported at $2,755. Among 4,814 Nurse Practitioner, Primary Care profiles paid that year, the median was $169 and the middle half received between $51 and $499.

Show as a table
Year Lauren Bradley Nurse Practitioner, Primary Care median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $1,297 $137 $39–$445 $132
2022 $2,190 $139 $44–$421 $149
2023 $3,132 $163 $53–$481 $160
2024 $1,879 $176 $54–$511 $164
2025 $2,755 $169 $51–$499 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Neurelis, Inc. $1,434 36 payments
  2. UCB, Inc. $1,387 51 payments
  3. ACADIA Pharmaceuticals Inc $1,133 6 payments
  4. Catalyst Pharmaceuticals, Inc. $819 35 payments
  5. Jazz Pharmaceuticals Inc. $604 25 payments
  6. LivaNova USA, Inc. $599 23 payments
  7. Ipsen Biopharmaceuticals, Inc $327 12 payments
  8. ALK-Abello, Inc $307 3 payments
  9. Aucta Pharmaceuticals, Inc. $266 11 payments
  10. Genzyme Corporation $266 2 payments
  11. Other $4,111 153 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $10,253 356 payments
  2. Consulting Fee $1,000 1 payment
Products named General payments · program years 2021–2025
  1. VALTOCO $1,434 36 payments
  2. DAYBUE $1,133 6 payments
  3. Epidiolex $604 25 payments
  4. Briviact $583 20 payments
  5. Fintepla $524 24 payments
  6. FYCOMPA $509 25 payments
  7. DYSPORT $327 12 payments
  8. VNS THERAPY SENTIVA MODEL 1000 GENERATOR $313 14 payments
  9. APTIOM $294 20 payments
  10. Motpoly XR $266 11 payments
  11. Other $4,680 154 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

357 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record